AGS Associates

AGS Associates

Personalbeschaffung und Rekrutierung

Accelerating Your Growth Potential

Über uns

AGS Associates is a distinguished Executive Search and Consulting firm. We have decades of experience connecting industry experts with clients ranging from innovative start-ups to globally established corporations. Through utilising forward-thinking principles, cutting-edge technology, and comprehensive research methods, our mission is to cultivate long-term, sustainable partnerships with our clients by providing them with best-in-class talent. Our continued investment into our people and technology ensures that our consultants are highly skilled, knowledgeable, and efficient. This, matched with our commitment to excellence and collaboration, means that we consistently offer modern and innovative solutions, enabling us to effortlessly build sustainable relationships with our clients. AGS is the partner of choice for Leadership Succession, Executive Search, Talent Mapping and Consulting services. We genuinely understand our client’s leadership challenges and can offer the appropriate, sustainable solution in an accelerated timeline because of our unrivalled access to the industries most sought-after talent. Our accelerated growth model combines the traditional approach of talent management with advanced data analytics, which ensures our consultants can support our candidates secure premium opportunities that will launch their careers forward.

Website
http://www.agsassociates.com
Industrie
Personalbeschaffung und Rekrutierung
Größe des Unternehmens
11-50 Mitarbeiter
Hauptsitz
London
Typ
In Privatbesitz
Gegründet
2021
Spezialitäten
Infrastructure, Life Science, Built Environment, and Commercial Building

Standorte

Employees at AGS Associates

Aktualisierungen

  • View organization page for AGS Associates, graphic

    4,066 followers

    Autobahn raises $100M on investor interest in neuropysch drugs 🧠 San Diego biotechnology company Autobahn Therapeutics on Wednesday said it raised $100M to advance an experimental mood disorder medicine into mid-stage testing. The company, which launched in 2020, is developing the drug for major depressive disorder and bipolar disorder depression. Called ABX-002, the drug works in a somewhat similar fashion to Madrigal Pharmaceuticals' Rezdiffra, by stimulating thyroid hormone receptors. Psychiatrists have used synthetic thyroid hormone off-label for years to treat depression, but the drugs aren't approved for that use and come with the risk of cardiac side effects. Psychiatry drugs have drawn more investment from pharma recently, with big buyouts of schizophrenia drug-makers Karuna Therapeutics and Cerevel Therapeutics two notable examples.

    Autobahn raises $100M on investor interest in neuropsych drugs

    Autobahn raises $100M on investor interest in neuropsych drugs

    biopharmadive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    Let the games begin: A glimpse at Paris' new Olympic venues 🏟 Despite hosting 10,000 athletes competing in 329 medal events at the Summer Games, the city has seen the construction of only a few new sports facilities. Opened in May, the Aquatics Centre venue cost $190M and was built by Paris-based Bouygues Construction. Additionally, the open-air Le Bourget Sports Climbing venue will be a permanent fixture after the Games are over. The Porte de la Chapelle Arena is the site for badminton and rhythmic gymnastics - it was the only new venue to be built in the middle of the city for the Games. The arena has a capacity of 8,000 and will also host badminton and powerlifting at this year's Paris Paralympic Games. The lack of major new construction in Paris is a departure from previous Olympics. In 2021, eight new permanent venues and ten temporary facilities went up for the Tokyo Games.

    Let the games begin: A glimpse at Paris’ new Olympic venues

    Let the games begin: A glimpse at Paris’ new Olympic venues

    constructiondive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    Reach out to Anna Reed directly if you're interested in joining our London team! We are currently hiring for our July and September Development Programmes.

    View profile for Anna Reed, graphic

    Senior Consultant at AGS Associates

    AGS Associates is hiring for our July and September Development Programmes 📅 AGS' training and development programmes accelerate careers. Our comprehensive classroom workshops, led by our in-house development coach, combined with on-the-job learning from experienced talent experts will ensure you have access to all the skills needed to become a successful Consultant and a future business leader. Please contact me via LinkedIn or email ([email protected]) if you're interested in joining our London team!

  • View organization page for AGS Associates, graphic

    4,066 followers

    Please reach out to Anna Reed ([email protected]) if you are interested in joining AGS Associates for our July and September Development Programmes.

    View profile for Anna Reed, graphic

    Senior Consultant at AGS Associates

    AGS Associates is hiring for our July and September Development Programmes 📅 AGS' training and development programmes accelerate careers. Our comprehensive classroom workshops, led by our in-house development coach, combined with on-the-job learning from experienced talent experts will ensure you have access to all the skills needed to become a successful Consultant and a future business leader. Please contact me via LinkedIn or email ([email protected]) if you're interested in learning more.

  • View organization page for AGS Associates, graphic

    4,066 followers

    Brain drug developer Alto Neuroscience prices $129M IPO 💵 Another biotechnology company has hit Wall Street via an initial public offering, the third to do so this year in an uptick of IPO activity that suggests rebounding investor interest in life sciences stocks. Alto Neuroscience raised about $129M on Thursday, selling 8,040,000 shares at $16 apiece. Alto's pricing follows January IPOs from CG Oncology and Arrivent Biopharma. Combined, the three have raised $684M, significantly more than what the first three biotechs to price IPOs last year raised. Alto is developing drugs for central nervous system diseases, focused on conditions such as major depressive disorder, post-traumatic stress disorder and schizophrenia. Its approach relies on developing new biomarkers to identify people most likely to respond to its treatments. #biopharma #neuroscience #ipo #biopharmaipo

    Brain drug developer Alto Neuroscience prices $129M IPO

    Brain drug developer Alto Neuroscience prices $129M IPO

    biopharmadive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    Walmart announces ambitious 5-year growth plan 🛒 Walmart announced Wednesday a five year plan to build or convert more than 150 locations while simultaneously continuing its efforts to remodel existing stores. Over the next 12 months, the retail giant said it aims to remodel 650 stores across 47 states and Puerto Rico. President and CEO John Furner said the company is 'finalizing construction plans' on 12 new stores it aims to start building this year. Neighbourhood Markets in Santa Rosa Beach, Florida, and Atlanta will be the first locations to open later this spring. The newly opened and remodelled locations are also more sustainable than previous builds, with energy-efficient equipment and lighting, lower-impact refrigerants and more. #construction #constructionindustry #commercialconstruction #walmart

    Walmart announces ambitious 5-year growth plan

    Walmart announces ambitious 5-year growth plan

    constructiondive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    4 heart device trends shaping the medtech sector in 2024 ❤️ Medical technology companies in 2024 are launching devices that address two especially vexing challenges affecting millions of heart patients: high blood pressure and atrial fibrillation. Heart device heavyweights are focusing on pulsed field ablation; Medtronic, Boston Scientific, J&J and Abbott are all pursuing this emerging market. Boston Scientific faces challengers in left atrial appendage treatment; both Medtronic and J&J announced the acquisition of similar devices in late 2023. Reimbursement is key as Medtronic forges new ground in hypertension; Medtronic has brought one of the first device-based treatments to the market for patients with uncontrolled high blood pressure and risk of heart attack or stroke. Valve leader Edwards is targeting a wider patient population as heart valve procedures have been slow to bounce back after the COVID-19 pandemic. #medtech #medtechindustry #heart #medicaltechnology

    4 heart device trends shaping the medtech sector in 2024

    4 heart device trends shaping the medtech sector in 2024

    medtechdive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    US hotel openings to watch in 2024 🛏 In the third quarter of 2023, several hotel companies posted record development pipelines. The pipeline of ground-up builds is increasingly dominated by the growing luxury and lifestyle segment. This year, new hotels will cater to the growing number of travellers seeking luxury, sustainable stays and adventure and experiences. Some of the top hotel and resort projects to watch in 2024 include the Signia by Hilton in Atlanta and Le Meridien in Fort Worth Downtown. Set to open in the summer, Populus in Denver is billed as the U.S.'s first 'carbon positive' hotel and The Dunlin in South Carolina is one of Vogue magazine's most anticipated hotels for 2024. #construction #constructionindustry #hotelconstruction #USconstruction

    US hotel openings to watch in 2024

    US hotel openings to watch in 2024

    constructiondive.com

  • View organization page for AGS Associates, graphic

    4,066 followers

    The trends that will shape the biotech industry in 2024 📅 AI has completely shifted the paradigm in the biotech industry and provides the opportunity to save time in many different ways. The field now encompasses various RNA-based therapies and they are anticipating RNA technologies to become more complex. The CRISPR sector is poised for growth; it has opened up new doors for treating genetic disorders. In 2024, bioprinting and tissue engineering are expected to be significant trends in the bioengineering industry. One of the key trends is the increasing variety of stem cell types being used in research and development. The targeted protein degradation market is growing rapidly and is expected to continue its upward trajectory in 2024. Experts in the field believe that the biotech industry is poised for recovery in 2024, and one reason for that would be a favourable climate for M&A activity. #biotech #biotechindustry #biotechtrends #biotech2024

    The trends that will shape the biotech industry in 2024

    The trends that will shape the biotech industry in 2024

    https://www.labiotech.eu

Ähnliche Seiten

Jobs durchsuchen